Login

Join Now

Recent BioUtah News & Events

Everything Happening in Utah Life Sciences

March 21, 2024
BioUtah News
Seek Labs Appoints Renowned Life Sciences Innovator, Dr. Michael Paul, PhD, to Board of Directors

SALT LAKE CITY, UT, March 19, 2024 (Business Wire) – Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel CRISPR-based gene therapies, is pleased to announce the appointment of Michael Paul, PhD to its Board of Directors, effective March 18, 2024. With decades of experience in life sciences innovation, capital formation, […]

March 21, 2024
BioUtah News
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and Trademark Office has issued a patent that will strengthen its ability to deliver a tumor-informed, high-definition, molecular residual disease (MRD) assay to market. U.S. patent […]

March 21, 2024
BioUtah News
Wasatch Biolabs Launches Proprietary Targeted DNA Methylation Sequencing Service for Researchers and Healthcare Providers

HEBER CITY, Utah, Feb. 13, 2024 /PRNewswire/ — Wasatch Biolabs (WBL), a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies’ laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers. The technique is amplification and bisulfite conversion free, effectively bypassing the most common limitations of targeted methylation analysis […]

March 21, 2024
BioUtah News
Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address

Presentation included announcement of the opening of the new manufacturing facility in Salt Lake City, UT SALT LAKE CITY, March 21, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that in his keynote address […]

March 21, 2024
BioUtah News
NUSANO TO PRESENT ISOTOPE PRODUCTION CAPABILITIES AND COMMERCIALIZATION PLANS AT 7TH THERANOSTICS WORLD CONGRESS

VALENCIA, Calif. – March 20, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile. Greg Moffitt, Nusano Director of Target Development, will provide an overview of the company’s proprietary radioisotope production platform on Sunday, March 24. […]

March 21, 2024
BioUtah News
Merit Medical Launches the Micro ACE™ Advanced Micro-Access System

Micro ACE combines a unique balance of stiffness and resiliency to achieve successful micro-access in challenging cases SOUTH JORDAN, Utah, March 19, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced commercial release of its US Food and Drug Administration (FDA)-cleared Micro ACE Advanced Micro-Access System. […]

March 21, 2024
BioUtah News
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

March 17, 2024
BioUtah News
Renalytix’s Successful Completion of Upsized $12M Placing

Successful Completion of Upsized $12M Placing NEW YORK and SALT LAKE CITY, March 12, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is pleased to announce that following its announcement earlier today regarding a proposed Placing of Ordinary Shares (the “Launch Announcement“), it has successfully placed 46,801,872 Ordinary Shares (the “Placing Shares“) with both UK and US institutional […]

March 17, 2024
BioUtah News
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

The clinical laboratory real-time PCR multiplex test was designed using Co-Dx Co-Primers™ and licensed by the CDSCO for use in diagnostic procedures

March 17, 2024
BioUtah News
LARGE, REAL-WORLD STUDIES DEMONSTRATE CONTINUED EXCELLENT OUTCOMES FOR PATIENTS RECEIVING EDWARDS SAPIEN TAVR

LARGE, REAL-WORLD STUDIES DEMONSTRATE CONTINUED EXCELLENT OUTCOMES FOR PATIENTS RECEIVING EDWARDS SAPIEN TAVR

March 17, 2024
BioUtah News
March 17, 2024
BioUtah News
Recursion Announces Plans to Open New Office in London

Appoints Michael Bronstein as Scientific Advisor and launches recruiting effort to fill the first 20 open roles across technology and biology, establishing a hub for world-class TechBio talent in the heart of King’s Cross neighborhood

March 17, 2024
BioUtah News
Nomi Health, CHG Healthcare Partner to Meet Growing Need for Streamlined Care for Underserved Communities

Partnership closes gaps in care for high-needs commercial, Medicaid and Medicare populations

March 17, 2024
BioUtah News
Halia Therapeutics to Present at BIO-Europe Spring 2024 Conference

Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET

March 17, 2024
BioUtah News
Fabric Genomics Partners with Intermountain Children’s Health to Enhance Precision Diagnosis of Infants and Children Using Whole Genome Sequencing from Broad Clinical Labs

Fabric Genomics Partners with Intermountain Children’s Health to Enhance Precision Diagnosis of Infants and Children

March 17, 2024
BioUtah News
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)

Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk

March 17, 2024
BioUtah News Policy News
Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers

Final Amendments to Strengthen Air Toxics Standards for Ethylene Oxide Commercial Sterilizers

March 17, 2024
BioUtah News
Ordaōs Acquires the Carterra®LSA® Platform to Further Speed and Optimize Its Machine-Driven Drug Design System

Carterra technology will allow Ordaōs to accelerate its mission of leveraging advanced technologies to efficiently and effectively design novel life-changing therapies for patients in need.

March 16, 2024
BioUtah News
E&I Summit Recap

 It was another banner year for the Wilson Sonsini Entrepreneur & Investor Life Sciences Summit (E&I Summit), presented by BioUtah and the University of Utah Technology Licensing Office. The 2024 E&I Summit included activities from March 13-15 with the main Summit event held, March 14 at the Sheraton in Salt Lake City. Over 450 registrants […]

March 7, 2024
BioUtah News
MAUNA KEA TECHNOLOGIES PARTNERS WITH METRODORA TO CREATE FIRST U.S. CENTER OF EXCELLENCE FOR THE USE OF CELLVIZIO® TO IDENTIFY AND TREAT FOOD INTOLERANCE IN ADULTS

Cellvizio Food Intolerance Test (C-FIT) delivers real-time, in vivo visibility to accurately identify food intolerance in patients suffering from Irritable Bowel Syndrome (IBS) Metrodora will serve as Center of Excellence for patient care and physician training to enable broad access to this breakthrough procedure Paris, Boston and Salt Lake City, March 6, 2024 – 5:45 […]

March 7, 2024
BioUtah News
Constant Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of TXA127 in Duchenne Muscular Dystrophy-Associated Cardiomyopathy

BOSTON, March 4, 2024 /PRNewswire/ — Constant Therapeutics LLC, a biopharmaceutical company focused on the development of treatments impacting the Alternative Renin-Angiotensin System, today announced that the first patient was dosed March 3, 2024, in the Company’s phase 2 clinical trial of TXA127, the Company’s lead peptide product under development as a potential treatment for […]

March 7, 2024
BioUtah News
Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink

Offer Now Scheduled to Expire at 5:00 p.m., New York Time, on April 30, 2024 WALTHAM, Mass.–(BUSINESS WIRE)– Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, Orion Acquisition AB (the “Buyer”), has extended the expiration time of the offering period of its previously […]

March 1, 2024
BioUtah News
Renalytix Expands US Government Coverage for FDA Approved kidneyintelX.dkd Testing at $950

Data to be Presented Today at NGS Open Meeting Demonstrating Clinical Value of KidneyIntelX LONDON and SALT LAKE CITY, February 29, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) announces that effective March 1, 2024, the United States Government has approved adding the company’s Food and Drug Administration (“FDA”) de Novo Marketing authorized test, kidneyintelX.dkd, to its […]

February 29, 2024
BioUtah News
Utah Legislative Recap, February 29, 2024

Funding Requests   Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]